Inactive Instrument

Lipum AB Stock

LIPUM

SE0015660899

Analysts' recommendations: Lipum AB

29/10/24	Västra hamnen raises motivated value for Lipum	FW
09/08/24	Redeye positive on Lipum's clinical progress - maintains motivated value of SEK 15	FW
29/05/24	Västra Hamnen initiates coverage of Lipum with a motivated value of SEK 10.81 per share	FW
24/04/24	Redeye adjusts motivated value for Lipum after rights issue	FW
24/04/24	Redeye lowers motivated value for Lipum to SEK 15 (20)	FW

More recommendations

Managers and Directors: Lipum AB

Manager	Title	Age	Since
Ola Sandborgh CEO	Chief Executive Officer	-	01/12/2023
Susanne Eva Lindqvist CTO	Chief Tech/Sci/R&D Officer	66	17/06/2010
Tobias Helgesson DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Olle Carl Hernell BRD	Director/Board Member	81	17/06/2010
Kristian Sandberg BRD	Director/Board Member	-	01/01/2019
Åsa Kristina Hansdotter BRD	Director/Board Member	52	01/01/2021

More insiders

Lipum AB (publ) is a Sweden-based biopharmaceutical company specialized in discovery and development of new treatment for chronic inflammatory diseases. Lipum develops new biological medicine for treatment of chronic inflammatory diseases eg rheumatoid arthritis. Development is based on results from preclinical research, for example in well-established animal models for inflammatory arthritis. The prospective drug is an antibody directed against a new target molecule, the protein Bile Salt-Stimulated Lipase (BSSL). Lipum's antibody (SOL-116) has a different mechanism of action than the other drugs. Lipum's drug candidate SOL-116 is a humanized monoclonal antibody and is therefore categorized as a biological drug.

Employees

Sector

Pharmaceuticals

Calendar

08-27 - Earnings release - Q2 2026

More about the company

Stock Market
Stocks
LIPUM Stock

The best tools reserved for subscribers to boost the performance of your investments!

03-20	Sweden's Lipum, Flerie Complete Merger	MT
03-20	Flerie completes merger with Lipum	FW
03-18	Calendar Wednesday March 18	FW
03-12	Lipum, Flerie Receives Swedish Regulatory Nod for Planned Merger	MT
03-12	Flerie, Lipum merger plan approved	RE
03-12	Flerie and Lipum receive approval to proceed with merger plan	FW
03-10	Lipum AB Receives for EUR 8 Million Grant from European Horizon Europe Research and Innovation Programme	CI
03-10	Lipum gets selected for Horizon Europe grant	RE
03-10	Lipum selected for 8 million euro EU grant	FW
02-25	Lipum Reports Expected Loss, Sets Sights on Phase 2 Study	FW
02-25	Lipum Oct-Dec loss at SEK 20.9 mln	RE
02-25	Lipum AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-25	Calendar Wednesday, February 25	FW

03-20	The merger between Flerie and Lipum has been completed	AQ
03-12	The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Lipum	AQ
03-10	Flerie’s portfolio company Lipum selected for EUR 8 million Horizon Europe grant	AQ
03-10	Lipum selected for Horizon Europe grant	AQ
02-26	Lipum (Q4 Reviev): Approaching merger completion	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIPUM AB	+0.70%	+7.09%	-	-	32.16M
REGENERON PHARMACEUTICALS, INC.	+4.73%	+3.38%	+19.53%	-8.89%	66.56B
UCB	-1.93%	+0.39%	+53.64%	+226.01%	56.51B
SAMSUNG BIOLOGICS CO.,LTD.	+1.07%	+42.10%	+42.10%	+42.10%	42.98B
CSL LIMITED	+3.45%	+6.04%	-49.82%	-55.95%	40.46B
BIOGEN INC.	+3.04%	+0.04%	+62.66%	-24.29%	31.91B
MODERNA, INC.	+10.01%	+18.57%	+161.59%	-34.48%	31.65B
INCYTE CORPORATION	+2.68%	+2.73%	+70.72%	+88.24%	23.35B
INNOVENT BIOLOGICS, INC.	+2.87%	+16.83%	+1.86%	+165.26%	19.46B
SWEDISH ORPHAN BIOVITRUM AB	-0.13%	+2.75%	+66.32%	+127.01%	17.18B
Average	+2.65%	+8.76%	+47.62%	+58.33%	36.67B
Weighted average by Cap.	+2.79%	+7.31%	+42.61%	+52.47%

Lipum AB Stock

Stocks

LIPUM

SE0015660899

Pharmaceuticals

Chart: Lipum AB

Latest news : Lipum AB

Analysts' recommendations: Lipum AB

Press Releases: Lipum AB

Quotes and Performance

Managers and Directors: Lipum AB

Biopharmaceuticals

Company Profile